- Home
- CDXS vs DSGN Comparison
CDXS vs DSGN Comparison
Compare CDXS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- DSGN
- Stock Information
- Founded
- CDXS 2002
- DSGN 2017
- Country
- CDXS United States
- DSGN United States
- Employees
- CDXS N/A
- DSGN N/A
- Industry
- CDXS Major Chemicals
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- DSGN Health Care
- Exchange
- CDXS Nasdaq
- DSGN Nasdaq
- Market Cap
- CDXS 176.4M
- DSGN 224.8M
- IPO Year
- CDXS 2010
- DSGN 2021
- Fundamental
- Price
- CDXS $2.47
- DSGN $3.45
- Analyst Decision
- CDXS Buy
- DSGN Hold
- Analyst Count
- CDXS 2
- DSGN 1
- Target Price
- CDXS $11.00
- DSGN $4.00
- AVG Volume (30 Days)
- CDXS 532.0K
- DSGN 138.7K
- Earning Date
- CDXS 05-14-2025
- DSGN 05-07-2025
- Dividend Yield
- CDXS N/A
- DSGN N/A
- EPS Growth
- CDXS N/A
- DSGN N/A
- EPS
- CDXS N/A
- DSGN N/A
- Revenue
- CDXS $59,345,000.00
- DSGN N/A
- Revenue This Year
- CDXS $12.62
- DSGN N/A
- Revenue Next Year
- CDXS $22.11
- DSGN N/A
- P/E Ratio
- CDXS N/A
- DSGN N/A
- Revenue Growth
- CDXS N/A
- DSGN N/A
- 52 Week Low
- CDXS $1.90
- DSGN $2.60
- 52 Week High
- CDXS $6.08
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CDXS 53.65
- DSGN 46.46
- Support Level
- CDXS $2.23
- DSGN $3.23
- Resistance Level
- CDXS $2.59
- DSGN $5.04
- Average True Range (ATR)
- CDXS 0.13
- DSGN 0.46
- MACD
- CDXS 0.05
- DSGN -0.04
- Stochastic Oscillator
- CDXS 81.82
- DSGN 27.19
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.